Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic MX-ICP Panel for Lung Cancer

Transgenomic has launched a multiplexed ICE COLD PCR (MX-ICP) lung cancer panel with epidermal growth factor receptor (EGFR) analysis. The panel covers key actionable mutations while providing precision detection levels as low as 0.01 percent. Characteristic mutations in EGFR are found in many patients with lung tumors, and these mutations may be associated with susceptibility or resistance to certain targeted cancer drugs. The panel includes EGFR exons 18-21 to determine NSCLC tumor sensitivity or resistance to tyrosine kinase inhibitors. The MX-ICP technology in the panel generates highly accurate results from small amounts of blood or tissue samples and is available for diagnostic use through the company's CLIA laboratory, said Transgenomic in a statement.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.